Cryoport, Inc. (CYRX) - Dilution Analysis

10-Q filing | 49.9M shares outstanding

10-Q filing | 50.3M shares outstanding

10-Q filing | 49.9M shares outstanding

10-K filing | 49.3M shares outstanding

10-Q filing | 49.4M shares outstanding

10-Q filing | 49.3M shares outstanding

8-K filing: Cryoport, Inc. authorized a repurchase program to purchase up to $200,000,000 of the Company's common stock and/or convertible senior notes and entered into agreements to repurchase approximately $160 million aggregate principal amount of its 2026 Notes at $885 per $1,000 principal amount.

10-Q filing | 49.0M shares outstanding

10-K filing | 49.0M shares outstanding

POS AM filing: CRYOPORT, INC. is offering and selling up to $100,000,000 in the aggregate of common stock, preferred stock, debt securities, depositary shares and purchase contracts from time to time in one or more offerings.

10-Q filing | 48.9M shares outstanding

10-Q filing | 48.7M shares outstanding

10-Q filing | 48.4M shares outstanding

10-K filing | 49.0M shares outstanding

10-Q filing | 48.5M shares outstanding

10-Q filing | 48.8M shares outstanding

10-Q filing | 49.7M shares outstanding

10-K filing | 0.2M shares outstanding

8-K filing: Cryoport, Inc. issued $402.5 million principal amount of 0.75% Convertible Senior Notes due 2026 and an aggregate of 3,072,038 shares of its common stock in a direct placement at a price of $81.10 per share. ($249.13M proceeds)

10-Q filing | 46.1M shares outstanding

10-Q filing | 45.9M shares outstanding

10-Q filing | 45.7M shares outstanding

10-K filing | 39.8M shares outstanding

8-K filing: Cryoport, Inc. issued 1,312,860 shares of Common Stock upon conversion of 50,000 shares of Series C Convertible Preferred Stock by Blackstone Freeze Parent L.P. and Blackstone Tactical Opportunities Fund - FD L.P. at a conversion price of $38.6152 per share, effective February 5, 2021.

8-K filing: Cryoport, Inc. completed an underwritten public offering of 4,356,059 shares of its common stock at a public offering price per share of $66.00, resulting in net proceeds of approximately $269.7 million. ($287.5M proceeds)

10-Q filing | 39.0M shares outstanding

8-K filing: Cryoport, Inc. completed the acquisition of CRYOPDP and MVE Cryobiological, and in connection with the MVE Acquisition, issued 250,000 shares of Series C Convertible Preferred Stock and 675,536 shares of common stock in a private placement with Blackstone. ($275.0M proceeds)

8-K filing: Cryoport, Inc. entered into a Purchase Agreement to acquire Chart's MVE cryobiological storage business for $320 million and a Securities Purchase Agreement with BTO Freeze Parent L.P. to issue and sell shares of Series C Convertible Preferred Stock and Common Stock for an aggregate purchase price of $275 million. ($275.0M proceeds)

10-Q filing | 38.6M shares outstanding

8-K filing: Cryoport, Inc. issued $115 million in aggregate principal amount of 3.00% Convertible Senior Notes due 2025 to initial purchasers on May 26, 2020, which may be converted into a maximum of 5,531,500 shares of common stock.

10-Q filing | 38.1M shares outstanding

10-K filing | 37.6M shares outstanding